Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group
- 1 July 2010
- journal article
- review article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 69 (7) , 1360-1363
Abstract
Objective To assess the validity of the 6 min walk test (6MWT) in pulmonary arterial hypertension secondary to systemic sclerosis (PAH-SSc) according to the OMERACT filter. Methods A systematic literature search was conducted from 1966 through June 2009. The assessment of validation of the 6MWT was based on the OMERACT filter criteria with the domains ‘truth’, ‘discrimination’ and ‘feasibility’. Results From the 57 articles identified, 9 (16%) were analysed. The 6MWT had face validity as it has been accepted by the registration agencies as a surrogate of PAH-SSc. It was sensitive to change in response to therapy, with effect sizes ranging from 0.30 to 1.37 with a parallel variation of haemodynamic parameters measured by right heart catheterisation. Feasibility was also validated. Content validity was not confirmed as this test was not specific for PAH-SSc. There was some evidence that 6MWT might meet criterion/construct validity, reproducibility and sensitivity to change over time, but insufficient data were provided to fully validate these components. Conclusions Current evidence suggests partial validation of the 6MWT in PAH-SSc according to the OMERACT filter. Further dedicated studies are needed to validate completely the 6MWT in PAH-SSc, taking into account the comorbidities interfering with the 6MWT.Keywords
This publication has 17 references indexed in Scilit:
- The 6-minute walk test in scleroderma--how measuring everything measures nothingRheumatology, 2008
- Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: A Delphi consensus study with cluster analysisArthritis Care & Research, 2008
- Selective endothelinA receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue diseaseAnnals of the Rheumatic Diseases, 2007
- New therapeutic strategies in the management of systemic sclerosisExpert Opinion on Pharmacotherapy, 2007
- Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk testAnnals of the Rheumatic Diseases, 2007
- Reduced exercise capacity in systemic sclerosis patients without pulmonary involvementScandinavian Journal of Rheumatology, 2007
- Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensionsAnnals of the Rheumatic Diseases, 2006
- Systemic sclerosis associated pulmonary hypertension: improved survival in the current eraHeart, 2006
- Pulmonary hypertension is associated with impaired exercise performance in patients with systemic sclerosisScandinavian Journal of Rheumatology, 2000
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996